SARS-CoV-2 Top-Enroller Trial Phase 3: Chicago's CCRII Enrolls 300+ Patients

SARS-CoV-2 Top-Enroller Trial Phase 3: Chicago's CCRII Enrolls 300+ Patients

Chicago Clinical Research Institute, Inc. is sharing news of their latest successes and research developments in the global battle against Covid-19.

As nationally accredited leaders in the fight against Covid-19, Chicago Clinical Research Institute has previously collaborated with AstraZeneca for a Covid-19 prophylaxis study.

They also worked with Sanofi on the Covid-19 vaccine study that helped to pave the way for the mass vaccination rollouts which have taken place internationally.

Now, with their latest trial, they are proud to announce to you their partnership with Regeneron, a leading biotechnology and pharmaceutical company based in New York.

Chicago Clinical Research Institute believes it is imperative that we continue to learn from SARS-CoV-2; understanding that the adaptable strain may precipitate further pandemics.

Chicago Clinical Research Institute’s recent top enroller trial used over 300 patients to test the monoclonal-antibody combination known as AZD7442, in a single intramuscular dose.

Their findings have now been published in The New England Journal of Medicine and show the monoclonal-antibody AZD7442 has efficacy as a preexposure and postexposure prophylaxis.

Go to https://ccrii.us to find out more.